ASSET PURCHASE AGREEMENT by and among ERYTECH PHARMA, S.A., ERYTECH PHARMA, INC., CATALENT PRINCETON, LLC and CATALENT PHARMA SOLUTIONS, INC. (solely for purposes of Section 6.17) dated as of April 22, 2022Asset Purchase Agreement • April 28th, 2022 • Erytech Pharma S.A. • Biological products, (no disgnostic substances) • Delaware
ASSET PURCHASE AGREEMENT, dated as of April 22, 2022 (this “Agreement”), by and among Erytech Pharma S.A., a French societé anonyme (“Seller”), Erytech Pharma, Inc., a Delaware corporation (“Erytech Inc.”), Catalent Princeton, LLC, a Delaware limited liability company (“Purchaser”) and, solely for purposes of Section 6.17, Catalent Pharma Solutions, Inc., a Delaware corporation (“Purchaser Parent”).
